90226-63-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(Cyclohexyloxy)ethylamine is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicinal compounds. Its reactivity and functional groups make it a valuable component in the creation of diverse therapeutic agents.
Used in Surfactant Production:
In the chemical industry, 2-(Cyclohexyloxy)ethylamine is utilized as a key ingredient in the production of surfactants. It aids in enhancing the properties of these compounds, such as their ability to reduce surface tension and emulsify substances, which are crucial for various applications in cleaning products and industrial processes.
Used in Corrosion Inhibition:
2-(Cyclohexyloxy)ethylamine serves as a corrosion inhibitor, protecting metals from degradation in various industrial settings. Its application helps to extend the lifespan of metal components and equipment, reducing maintenance costs and downtime.
Used as a Catalyst in Polymerization Processes:
2-(cyclohexyloxy)ethylamine is also employed as a catalyst in polymerization reactions, facilitating the formation of polymers with specific properties. Its use in this capacity is instrumental in the plastics and materials science industries, enabling the production of tailored polymers for specialized applications.

Upstream product

• 151-56-4 ethyleneimine 
• 108-93-0 cyclohexanol 
• 71995-54-5 2-(cyclohexyloxy)acetic acid 
• 137211-72-4 methanesulfonic acid 2-cyclohexyloxy-ethyl ester 
• 1817-88-5 2-Cyclohexyloxyethanol 

Downstream Products

• 200400-39-1 N-[1-(2-cyclohexyloxy-ethylcarbamoyl)-2-hydroxy-ethyl]-4-(pyridine-3-carbonyl)-benzamide 
• 200400-47-1 (S)-2-[4-(Pyridine-3-carbonyl)-phenyl]-4,5-dihydro-oxazole-4-carboxylic acid (2-cyclohexyloxy-ethyl)-amide 
• 200400-55-1 N-<2-(cyclohexyloxy)ethyl>-2-<4-(3-pyridylcarbonyl)phenyl>-4-oxazolecarboxamide 
• 200400-22-2 2-amino-N-(2-cyclohexyloxy-ethyl)-3-hydroxy-propionamide 

Relevant academic research and scientific papers

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted ω-phenyl-ω-(3-pyridyl)alkenoic acid derivatives and related compounds

A novel series of oxazolecarboxamide-substituted ω-phenyl-ω-(3- pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA2 receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4- [4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept- 6-enoic acid (14) with K(d) = 9.9 ± 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 ± 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, 'shunt' effect to elevate PGI2 level, and absence of agonist activity.

Carbamoyl substituted heterocycles

This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

PREPARATION OF SUBSTITUTED ALKENOIC ACIDS

This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

Carbamoyl substituted oxazoles as thromboxane receptor antagonists

This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.